Brian Bramson

Brian Bramson

Auto-generated profile, based on publicly available information

Brian Bramson

Department of Medicine, Division of Infectious Diseases, University of North Carolina, School of Medicine , Chapel Hill, North Carolina , USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2005 in Journal of the International Association of Physicians in AIDS Care
Verified
Journal Article
Open access
PDF file
AKAthena P. Kourtis
Athena P. Kourtis
BBBrian Bramson
Brian Bramson
CHCharles van der Horst
Charles van der Horst
PKPeter Kazembe
Peter Kazembe
YAYusuf Ahmed
Yusuf Ahmed
UTUNC Project BAN Study Team
UNC Project BAN Study Team
Infants of African origin have a lower normal range of absolute neutrophil counts than white infants; this fact, however, remains under appreciated by clinical researchers in the United States. During the initial stages of a clinical trial in Malawi, the authors noted an unexpectedly high number of infants with absolute neutrophil counts that would be classifiable as neutropenic using the National Institutes of Health’s Division of AIDS toxicity tables. The authors argue that the relevant Division of AIDS table does not take into account the available evidence of low absolute neutrophil counts in African infants and that a systematic collection of data from many African settings might help establish the absolute neutrophil count cutpoints to be used for defining neutropenia in African populations.

19 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
CRCasey Allison Rimland
Casey Allison Rimland
CMCamille E. Morgan
Camille E. Morgan
GBGriffin Bell
Griffin Bell
MKMin K. Kim
Min K. Kim
THTanner Hedrick
Tanner Hedrick
JPJonathan B. Parr
Jonathan B. Parr
We describe early outcomes in 11 COVID-19 patients treated with the IL-6 receptor inhibitor tocilizumab. While C-reactive protein decreased, neither clinical improvement nor reduced temperature or oxygen requirements was observed in most patients. Our findings contrast with prior reports and raise questions about tocilizumab use in severe COVID-19.

9 September 2021 in Healthcare
Verified
Journal Article
Closed access
CMCamille E. Morgan
Camille E. Morgan
CRCasey A. Rimland
Casey A. Rimland
GBGriffin Bell
Griffin Bell
MKMin K. Kim
Min K. Kim
THTanner Hedrick
Tanner Hedrick
JPJonathan B. Parr
Jonathan B. Parr

14 June 2024 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
BBBrian Bramson
Brian Bramson
HKHoward Kashefsky
Howard Kashefsky
EKEmma Kashefsky
Emma Kashefsky
An 18-year-old man with a history of Crohn colitis who had begun treatment with infliximab 1 year earlier was referred to the infectious diseases clinic for treatment of latent tuberculous after a positive interferon γ release assay test (IGRA) result. Three weeks before his appointment the patient had begun oral terbinafine, prescribed by his primary care physician for an infection in his right great toe that had been present for >3 months. The patient stated that the infection had been progressing despite several courses of oral antibacterial antibiotics, including a 7-day course of cephalexin completed 1 week before presentation at the infectious diseases clinic. He did not note any improvement in the toe lesion since beginning the terbinafine. He reported that the toe lesion began after he cut his toe on a knife while visiting friends at a hunting lodge in the South Carolina lowlands 4 months before his presentation to clinic. He recalled that the cut was uncovered while he went bass fishing in a local estuary and rode all-terrain vehicles in the local marshes.